Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrexed as a first-line treatment in patients with unresectable, locally advanced or ...
Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...
Daryl Dixon Season 3 has concluded, and fans still can't stop thinking about these shocking moments from the AMC spin-off ...
The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.
ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...
In a recent conversation with Inverse, Del Toro expressed interest in adapting another literary classic – Gaston Leroux ’s ...
One Piece Chapter 1164's spoilers may have revealed some major details about the mysterious D clan and the Will of D within ...
What will happen to U.S. healthcare if the federal government shuts down next week? That question is on the minds of patients, providers, and health policy experts as the clock ticks down to Sept. 30, ...
Health Canada has granted a Notice of Compliance (NOC) for Enhertu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...
New research has uncovered a built-in resistance mechanism to antibody–drug conjugates in some breast cancers and identified ...
Shimadzu Asia Pacific joins the global celebration of Shimadzu Corporation's 150th anniversary, marking a century and a half ...
The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback